Company / Cost of Revenue
Travere Therapeutics, Inc. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$10.3M
FY2025
5-year range
$4.4M / $11.4M
FY2021-FY2025
Trend
+33.5%
vs FY2024
Sector context
#71 of 85
Health Care
What the data says
Travere Therapeutics, Inc.'s cost of revenue of $10M is lower than 84% of companies in the Health Care sector (FY2025). Cost of Revenue has fluctuated over the past 10 years, ranging from $571,000 in FY2016 to $11M in FY2023.
Based on SEC 10-K filings.
$10M in FY2025 with a 5-year CAGR of +13.3%.
Improved from $11M to $10M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +32.7%
- 5-Year CAGR
- +13.3%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 85This company $10.3M Sector average $2.0B
▼
-99.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +13.3%, indicating consistent growth.
- In FY2025, cost of revenue increased 33.5% year-over-year.
- Ranks #71 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.3M | +33.5% |
| FY2024 | $7.7M | -32.4% |
| FY2023 | $11.4M | +159.0% |
| FY2022 | $4.4M | -15.6% |
| FY2021 | $5.2M | -5.3% |
| FY2020 | $5.5M | +53.3% |
| FY2019 | $3.6M | -20.8% |
| FY2018 | $4.6M | +108.4% |
| FY2017 | $2.2M | +282.7% |
| FY2016 | $571.0K | -73.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026